Etanercept is effective in juvenile idiopathic arthritis (JIA).^1–,³ Currently it is administered subcutaneously at a dose of 0.4 mg/kg (maximum of 25 mg) twice a week. Clinical trials in adults show that administration of a double dose once a week is effective enough to induce and retain remission.^4,5 A pharmacokinetic model developed by Yim et al⁶ indicates that the same dosing regimen could be used in children. Wallace⁷ mentions the once weekly double dose in patients with JIA, but this is not supported by clinical trials. Therefore we evaluated the efficacy of etanercept administered subcutaneously once a week at a dose of …